An Early Phase 1 interventional study of Glucagon-Like Peptide- 1 (GLP-1) infusion and Placebo Comparator: Saline Infusion in Type 2 Diabetes Mellitus, sponsored by University of Maryland, Baltimore. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Maryland, Baltimore · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Glucagon-Like Peptide 1 · Diabetes Mellitus, Type 2.
Among the 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2, this one is the 5th largest by planned enrollment, is one of 2 that started in 2013, is the only one in phase 1, and was the 9th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark
Ages 23–64 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2013.
This study's planned enrollment of 28 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 20 across the 11 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 9 most frequent:
University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.
Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.
12 studies in Diabetes Mellitus, Type 2 by University of Maryland, Baltimore: 1 open now, 2 under way, none of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 12 studies in Diabetes Mellitus, Type 2 by University of Maryland, Baltimore, this one is the 7th largest by planned enrollment, is the only one that started in 2013, is one of 6 in phase 1, and was the 8th registered.
University of Maryland, Baltimore’s Diabetes Mellitus, Type 2 studies by the year they started, since 2007.
1 of the studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398300Copenhagen University Hospital, RigshospitaletInsulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion | 2027-03-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing Glucagon-Like Peptide 1 in Diabetes Mellitus, Type 2, from their registry updates:
Among University of Maryland, Baltimore’s 12 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infusion of GLP-1 during experimental period
Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion
Saline infusion during experimental period
Other: Placebo Comparator: Saline Infusion
GLP-1 infusion during experimental period
Also known as: GLP-1
Saline infusion (placebo) during experimental period
Also known as: Saline infusion
Change in Plasminogen Activation inhibitor-1 (PAi-1)
measurements of change in PAi-1 at baseline and during the end of the glucose clamp period (2 hours)
Time frame: change from baseline to end of clamp period
Change in Flow mediated dilation (FMD)
flow mediated dilation of the brachial artery will be measured for change from baseline and end of glucose clamp (\~4 hours)
Time frame: change from baseline and end of clamp
Ran from Jul 2013 to primary completion in Feb 2026, 151 months.
Of 63 non-industry phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's 151 months is above that.
Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Feb 2026 and completion Dec 2026 → Feb 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glucagon-Like Peptide 1
University of Maryland, Baltimore →